Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Masimo Corporation (NASDAQ:MASI) announced that William Jellison resigned from its Board of Directors effective Monday. According to a statement in a press release filed with the Securities and Exchange Commission, the company reported that Mr. Jellison’s resignation was not due to any disagreement with Masimo regarding its operations, policies, or practices.
Michelle Brennan, Chairman of the Board, expressed appreciation for Mr. Jellison’s service and contributions during his tenure. The company did not disclose plans for appointing a successor.
Masimo, based in Irvine, California, develops electromedical and electrotherapeutic apparatus. The information in this article is based on the company’s recent SEC filing.
In other recent news, Masimo has announced its second-quarter 2025 financial results, reporting sales of $370.9 million, which surpassed analyst expectations. This figure exceeded both Stifel’s and consensus estimates, marking a 7.7% year-over-year increase when excluding foreign exchange effects. Despite this growth, Masimo’s overall revenue growth slowed to 7% on a constant currency basis, compared to 10% in the first quarter of 2025. Stifel has reiterated its Buy rating with a $180.00 price target, while Needham has maintained a Hold rating following the earnings report. Additionally, Masimo has received FDA 510(k) clearance for expanded indications of its delta hemoglobin parameters in O3 Regional Oximetry, now available for cerebral and somatic applications across all patient populations. In a related development, BTIG has reiterated its Buy rating and set a $198.00 price target on Masimo stock amid Apple (NASDAQ:AAPL)’s announcement of reintroducing its Blood Oxygen feature for Apple Watch models. This follows a U.S. Customs ruling that affected Apple Watches sold in the U.S. Previously, the feature was removed due to a patent infringement lawsuit involving Masimo.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.